Industry Research Reports
Part 1
Part 2
Part 3
Part 5
Home > Reports >
Pharma & Healthcare
>
Global Mitochondrial-based Therapeutics Market Report, History and Forecast 2018-2029, Breakdown Data by Companies, Key Regions, Types and Application
Global Mitochondrial-based Therapeutics Market Report, History and Forecast 2018-2029, Breakdown Data by Companies, Key Regions, Types and Application
-
Description
- Table of Contents
- Table of Figures
- PDF Download
-
Description
- Table of Contents
- Table of Figures
- PDF Download
Description
Mitochondria are therefore vital for normal cellular function, including intracellular metabolic activities and signal transduction of various cellular pathways. They are involved in cellular ion homeostasis, oxidative stress, and apoptotic and necrotic cell death. Mitochondrial-based Therapeutics report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Mitochondrial-based Therapeutics market is projected to reach US$ 651.3 million in 2029, increasing from US$ 379 million in 2022, with the CAGR of 7.8% during the period of 2023 to 2029. Demand from Mitochondrial Myopathy and Leber’s heredity Optic Neuropathy are the major drivers for the industry.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Mitochondrial-based Therapeutics market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report:
By Company
Reneo Pharmaceutical
Pfizer Inc.
Norvartis AG
Takeda Pharmaceuticals
Amgen Inc.
NeuroVive Pharmaceutical AB
Entogene AG
Stealth Biotherapeutics
Ixchel Pharma
Reata Pharmaceuticals
Segment by Type
Oral
Intravenous
Segment by Application
Mitochondrial Myopathy
Leber’s heredity Optic Neuropathy
Leigh Syndrome
Mitochondrial DNA Depletion Syndrome
Other
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Mitochondrial-based Therapeutics market further:
Chapter 1: Global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029).
Chapter 2: Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 3: Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 4: Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Companies’ Outline, covering company’s basic information, Mitochondrial-based Therapeutics introduction, etc. Mitochondrial-based Therapeutics Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10: Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11: Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12: QYResearch’s Conclusions of Mitochondrial-based Therapeutics market based on comprehensive survey.
Chapter 13: Methodology and Data Sources adopted by QYResearch. Table of Contents
1 Market Overview of Mitochondrial-based Therapeutics
1.1 Mitochondrial-based Therapeutics Market Overview
1.1.1 Mitochondrial-based Therapeutics Product Scope
1.1.2 Mitochondrial-based Therapeutics Market Status and Outlook
1.2 Global Mitochondrial-based Therapeutics Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Mitochondrial-based Therapeutics Market Size by Region (2018-2029)
1.4 Global Mitochondrial-based Therapeutics Historic Market Size by Region (2018-2023)
1.5 Global Mitochondrial-based Therapeutics Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Mitochondrial-based Therapeutics Market Size (2018-2029)
1.6.1 North America Mitochondrial-based Therapeutics Market Size (2018-2029)
1.6.2 Europe Mitochondrial-based Therapeutics Market Size (2018-2029)
1.6.3 Asia-Pacific Mitochondrial-based Therapeutics Market Size (2018-2029)
1.6.4 Latin America Mitochondrial-based Therapeutics Market Size (2018-2029)
1.6.5 Middle East & Africa Mitochondrial-based Therapeutics Market Size (2018-2029)
2.1 Introduction
2.1.1 Oral
2.1.2 Intravenous
2.2 Global Mitochondrial-based Therapeutics Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Mitochondrial-based Therapeutics Historic Market Size by Type (2018-2023)
2.2.2 Global Mitochondrial-based Therapeutics Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Mitochondrial-based Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Mitochondrial-based Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Mitochondrial-based Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Mitochondrial-based Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Mitochondrial-based Therapeutics Revenue Breakdown by Type (2018-2029)
3.1 Introduction
3.1.1 Mitochondrial Myopathy
3.1.2 Leber’s heredity Optic Neuropathy
3.1.3 Leigh Syndrome
3.1.4 Mitochondrial DNA Depletion Syndrome
3.1.5 Other
3.2 Global Mitochondrial-based Therapeutics Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Mitochondrial-based Therapeutics Historic Market Size by Application (2018-2023)
3.2.2 Global Mitochondrial-based Therapeutics Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Mitochondrial-based Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Mitochondrial-based Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Mitochondrial-based Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Mitochondrial-based Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Mitochondrial-based Therapeutics Revenue Breakdown by Application (2018-2029)
4.1 Global Mitochondrial-based Therapeutics Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Mitochondrial-based Therapeutics as of 2022)
4.3 Date of Key Players Enter into Mitochondrial-based Therapeutics Market
4.4 Global Top Players Mitochondrial-based Therapeutics Headquarters and Area Served
4.5 Key Players Mitochondrial-based Therapeutics Product Solution and Service
4.6 Competitive Status
4.6.1 Mitochondrial-based Therapeutics Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5.1 Reneo Pharmaceutical
5.1.1 Reneo Pharmaceutical Profile
5.1.2 Reneo Pharmaceutical Main Business
5.1.3 Reneo Pharmaceutical Mitochondrial-based Therapeutics Products, Services and Solutions
5.1.4 Reneo Pharmaceutical Mitochondrial-based Therapeutics Revenue (US$ Million) & (2018-2023)
5.1.5 Reneo Pharmaceutical Recent Developments
5.2 Pfizer Inc.
5.2.1 Pfizer Inc. Profile
5.2.2 Pfizer Inc. Main Business
5.2.3 Pfizer Inc. Mitochondrial-based Therapeutics Products, Services and Solutions
5.2.4 Pfizer Inc. Mitochondrial-based Therapeutics Revenue (US$ Million) & (2018-2023)
5.2.5 Pfizer Inc. Recent Developments
5.3 Norvartis AG
5.3.1 Norvartis AG Profile
5.3.2 Norvartis AG Main Business
5.3.3 Norvartis AG Mitochondrial-based Therapeutics Products, Services and Solutions
5.3.4 Norvartis AG Mitochondrial-based Therapeutics Revenue (US$ Million) & (2018-2023)
5.3.5 Takeda Pharmaceuticals Recent Developments
5.4 Takeda Pharmaceuticals
5.4.1 Takeda Pharmaceuticals Profile
5.4.2 Takeda Pharmaceuticals Main Business
5.4.3 Takeda Pharmaceuticals Mitochondrial-based Therapeutics Products, Services and Solutions
5.4.4 Takeda Pharmaceuticals Mitochondrial-based Therapeutics Revenue (US$ Million) & (2018-2023)
5.4.5 Takeda Pharmaceuticals Recent Developments
5.5 Amgen Inc.
5.5.1 Amgen Inc. Profile
5.5.2 Amgen Inc. Main Business
5.5.3 Amgen Inc. Mitochondrial-based Therapeutics Products, Services and Solutions
5.5.4 Amgen Inc. Mitochondrial-based Therapeutics Revenue (US$ Million) & (2018-2023)
5.5.5 Amgen Inc. Recent Developments
5.6 NeuroVive Pharmaceutical AB
5.6.1 NeuroVive Pharmaceutical AB Profile
5.6.2 NeuroVive Pharmaceutical AB Main Business
5.6.3 NeuroVive Pharmaceutical AB Mitochondrial-based Therapeutics Products, Services and Solutions
5.6.4 NeuroVive Pharmaceutical AB Mitochondrial-based Therapeutics Revenue (US$ Million) & (2018-2023)
5.6.5 NeuroVive Pharmaceutical AB Recent Developments
5.7 Entogene AG
5.7.1 Entogene AG Profile
5.7.2 Entogene AG Main Business
5.7.3 Entogene AG Mitochondrial-based Therapeutics Products, Services and Solutions
5.7.4 Entogene AG Mitochondrial-based Therapeutics Revenue (US$ Million) & (2018-2023)
5.7.5 Entogene AG Recent Developments
5.8 Stealth Biotherapeutics
5.8.1 Stealth Biotherapeutics Profile
5.8.2 Stealth Biotherapeutics Main Business
5.8.3 Stealth Biotherapeutics Mitochondrial-based Therapeutics Products, Services and Solutions
5.8.4 Stealth Biotherapeutics Mitochondrial-based Therapeutics Revenue (US$ Million) & (2018-2023)
5.8.5 Stealth Biotherapeutics Recent Developments
5.9 Ixchel Pharma
5.9.1 Ixchel Pharma Profile
5.9.2 Ixchel Pharma Main Business
5.9.3 Ixchel Pharma Mitochondrial-based Therapeutics Products, Services and Solutions
5.9.4 Ixchel Pharma Mitochondrial-based Therapeutics Revenue (US$ Million) & (2018-2023)
5.9.5 Ixchel Pharma Recent Developments
5.10 Reata Pharmaceuticals
5.10.1 Reata Pharmaceuticals Profile
5.10.2 Reata Pharmaceuticals Main Business
5.10.3 Reata Pharmaceuticals Mitochondrial-based Therapeutics Products, Services and Solutions
5.10.4 Reata Pharmaceuticals Mitochondrial-based Therapeutics Revenue (US$ Million) & (2018-2023)
5.10.5 Reata Pharmaceuticals Recent Developments
6.1 North America Mitochondrial-based Therapeutics Market Size by Country (2018-2029)
6.2 United States
6.3 Canada
7.1 Europe Mitochondrial-based Therapeutics Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8.1 Asia-Pacific Mitochondrial-based Therapeutics Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9.1 Latin America Mitochondrial-based Therapeutics Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10.1 Middle East & Africa Mitochondrial-based Therapeutics Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11.1 Mitochondrial-based Therapeutics Industry Trends
11.2 Mitochondrial-based Therapeutics Market Drivers
11.3 Mitochondrial-based Therapeutics Market Challenges
11.4 Mitochondrial-based Therapeutics Market Restraints
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Table of Figures
List of Tables
Table 1. Global Market Mitochondrial-based Therapeutics Market Size (US$ Million) Comparison by Region 2018 VS 2022 VS 2029
Table 2. Global Mitochondrial-based Therapeutics Market Size by Region (2018-2023) & (US$ Million)
Table 3. Global Mitochondrial-based Therapeutics Market Size Share by Region (2018-2023)
Table 4. Global Mitochondrial-based Therapeutics Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 5. Global Mitochondrial-based Therapeutics Forecasted Market Size Share by Region (2024-2029)
Table 6. Global Mitochondrial-based Therapeutics Market Size (US$ Million) by Type: 2018 VS 2022 VS 2029
Table 7. Global Mitochondrial-based Therapeutics Market Size by Type (2018-2023) & (US$ Million)
Table 8. Global Mitochondrial-based Therapeutics Revenue Market Share by Type (2018-2023)
Table 9. Global Mitochondrial-based Therapeutics Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 10. Global Mitochondrial-based Therapeutics Revenue Market Share by Type (2024-2029)
Table 11. North America Mitochondrial-based Therapeutics Revenue by Type (2018-2023) & (US$ Million)
Table 12. North America Mitochondrial-based Therapeutics Revenue by Type (2024-2029) & (US$ Million)
Table 13. Europe Mitochondrial-based Therapeutics Revenue by Type (2018-2023) & (US$ Million)
Table 14. Europe Mitochondrial-based Therapeutics Revenue by Type (2024-2029) & (US$ Million)
Table 15. Asia-Pacific Mitochondrial-based Therapeutics Revenue by Type (2018-2023) & (US$ Million)
Table 16. Asia-Pacific Mitochondrial-based Therapeutics Revenue by Type (2024-2029) & (US$ Million)
Table 17. Latin America Mitochondrial-based Therapeutics Revenue by Type (2018-2023) & (US$ Million)
Table 18. Latin America Mitochondrial-based Therapeutics Revenue by Type (2024-2029) & (US$ Million)
Table 19. Middle East and Africa Mitochondrial-based Therapeutics Revenue by Type (2018-2023) & (US$ Million)
Table 20. Middle East and Africa Mitochondrial-based Therapeutics Revenue by Type (2024-2029) & (US$ Million)
Table 21. Global Mitochondrial-based Therapeutics Market Size (US$ Million) by Application: 2018 VS 2022 VS 2029
Table 22. Global Mitochondrial-based Therapeutics Market Size by Application (2018-2023) & (US$ Million)
Table 23. Global Mitochondrial-based Therapeutics Revenue Market Share by Application (2018-2023)
Table 24. Global Mitochondrial-based Therapeutics Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 25. Global Mitochondrial-based Therapeutics Revenue Market Share by Application (2024-2029)
Table 26. North America Mitochondrial-based Therapeutics Revenue by Application (2018-2023) & (US$ Million)
Table 27. North America Mitochondrial-based Therapeutics Revenue by Application (2024-2029) & (US$ Million)
Table 28. Europe Mitochondrial-based Therapeutics Revenue by Application (2018-2023) & (US$ Million)
Table 29. Europe Mitochondrial-based Therapeutics Revenue by Application (2024-2029) & (US$ Million)
Table 30. Asia-Pacific Mitochondrial-based Therapeutics Revenue by Application (2018-2023) & (US$ Million)
Table 31. Asia-Pacific Mitochondrial-based Therapeutics Revenue by Application (2024-2029) & (US$ Million)
Table 32. Latin America Mitochondrial-based Therapeutics Revenue by Application (2018-2023) & (US$ Million)
Table 33. Latin America Mitochondrial-based Therapeutics Revenue by Application (2024-2029) & (US$ Million)
Table 34. Middle East and Africa Mitochondrial-based Therapeutics Revenue by Application (2018-2023) & (US$ Million)
Table 35. Middle East and Africa Mitochondrial-based Therapeutics Revenue by Application (2024-2029) & (US$ Million)
Table 36. Global Mitochondrial-based Therapeutics Revenue (US$ Million) by Players (2018-2023)
Table 37. Global Mitochondrial-based Therapeutics Revenue Market Share by Players (2018-2023)
Table 38. Global Top Players Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Mitochondrial-based Therapeutics as of 2022)
Table 39. Date of Key Players Enter into Mitochondrial-based Therapeutics Market
Table 40. Global Mitochondrial-based Therapeutics Key Players Headquarters and Area Served
Table 41. Mitochondrial-based Therapeutics Product Solution and Service
Table 42. Global Mitochondrial-based Therapeutics Players Market Concentration Ratio (CR5 and HHI)
Table 43. Mergers & Acquisitions, Expansion Plans
Table 44. Reneo Pharmaceutical Basic Information List
Table 45. Reneo Pharmaceutical Description and Business Overview
Table 46. Reneo Pharmaceutical Mitochondrial-based Therapeutics Products, Services and Solutions
Table 47. Revenue (US$ Million) in Mitochondrial-based Therapeutics Business of Reneo Pharmaceutical (2018-2023)
Table 48. Reneo Pharmaceutical Recent Developments
Table 49. Pfizer Inc. Basic Information List
Table 50. Pfizer Inc. Description and Business Overview
Table 51. Pfizer Inc. Mitochondrial-based Therapeutics Products, Services and Solutions
Table 52. Revenue (US$ Million) in Mitochondrial-based Therapeutics Business of Pfizer Inc. (2018-2023)
Table 53. Pfizer Inc. Recent Developments
Table 54. Norvartis AG Basic Information List
Table 55. Norvartis AG Description and Business Overview
Table 56. Norvartis AG Mitochondrial-based Therapeutics Products, Services and Solutions
Table 57. Revenue (US$ Million) in Mitochondrial-based Therapeutics Business of Norvartis AG (2018-2023)
Table 58. Norvartis AG Recent Developments
Table 59. Takeda Pharmaceuticals Basic Information List
Table 60. Takeda Pharmaceuticals Description and Business Overview
Table 61. Takeda Pharmaceuticals Mitochondrial-based Therapeutics Products, Services and Solutions
Table 62. Revenue (US$ Million) in Mitochondrial-based Therapeutics Business of Takeda Pharmaceuticals (2018-2023)
Table 63. Takeda Pharmaceuticals Recent Developments
Table 64. Amgen Inc. Basic Information List
Table 65. Amgen Inc. Description and Business Overview
Table 66. Amgen Inc. Mitochondrial-based Therapeutics Products, Services and Solutions
Table 67. Revenue (US$ Million) in Mitochondrial-based Therapeutics Business of Amgen Inc. (2018-2023)
Table 68. Amgen Inc. Recent Developments
Table 69. NeuroVive Pharmaceutical AB Basic Information List
Table 70. NeuroVive Pharmaceutical AB Description and Business Overview
Table 71. NeuroVive Pharmaceutical AB Mitochondrial-based Therapeutics Products, Services and Solutions
Table 72. Revenue (US$ Million) in Mitochondrial-based Therapeutics Business of NeuroVive Pharmaceutical AB (2018-2023)
Table 73. NeuroVive Pharmaceutical AB Recent Developments
Table 74. Entogene AG Basic Information List
Table 75. Entogene AG Description and Business Overview
Table 76. Entogene AG Mitochondrial-based Therapeutics Products, Services and Solutions
Table 77. Revenue (US$ Million) in Mitochondrial-based Therapeutics Business of Entogene AG (2018-2023)
Table 78. Entogene AG Recent Developments
Table 79. Stealth Biotherapeutics Basic Information List
Table 80. Stealth Biotherapeutics Description and Business Overview
Table 81. Stealth Biotherapeutics Mitochondrial-based Therapeutics Products, Services and Solutions
Table 82. Revenue (US$ Million) in Mitochondrial-based Therapeutics Business of Stealth Biotherapeutics (2018-2023)
Table 83. Stealth Biotherapeutics Recent Developments
Table 84. Ixchel Pharma Basic Information List
Table 85. Ixchel Pharma Description and Business Overview
Table 86. Ixchel Pharma Mitochondrial-based Therapeutics Products, Services and Solutions
Table 87. Revenue (US$ Million) in Mitochondrial-based Therapeutics Business of Ixchel Pharma (2018-2023)
Table 88. Ixchel Pharma Recent Developments
Table 89. Reata Pharmaceuticals Basic Information List
Table 90. Reata Pharmaceuticals Description and Business Overview
Table 91. Reata Pharmaceuticals Mitochondrial-based Therapeutics Products, Services and Solutions
Table 92. Revenue (US$ Million) in Mitochondrial-based Therapeutics Business of Reata Pharmaceuticals (2018-2023)
Table 93. Reata Pharmaceuticals Recent Developments
Table 94. North America Mitochondrial-based Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 95. North America Mitochondrial-based Therapeutics Market Size by Country (2024-2029) & (US$ Million)
Table 96. Europe Mitochondrial-based Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 97. Europe Mitochondrial-based Therapeutics Market Size by Country (2024-2029) & (US$ Million)
Table 98. Asia-Pacific Mitochondrial-based Therapeutics Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 99. Asia-Pacific Mitochondrial-based Therapeutics Market Size by Region (2018-2023) & (US$ Million)
Table 100. Asia-Pacific Mitochondrial-based Therapeutics Market Size by Region (2024-2029) & (US$ Million)
Table 101. Asia-Pacific Mitochondrial-based Therapeutics Market Share by Region (2018-2023)
Table 102. Asia-Pacific Mitochondrial-based Therapeutics Market Share by Region (2024-2029)
Table 103. Latin America Mitochondrial-based Therapeutics Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 104. Latin America Mitochondrial-based Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 105. Latin America Mitochondrial-based Therapeutics Market Size by Country (2024-2029) & (US$ Million)
Table 106. Middle East & Africa Mitochondrial-based Therapeutics Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 107. Middle East & Africa Mitochondrial-based Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 108. Middle East & Africa Mitochondrial-based Therapeutics Market Size by Country (2024-2029) & (US$ Million)
Table 109. Mitochondrial-based Therapeutics Market Trends
Table 110. Mitochondrial-based Therapeutics Market Drivers
Table 111. Mitochondrial-based Therapeutics Market Challenges
Table 112. Mitochondrial-based Therapeutics Market Restraints
Table 113. Research Programs/Design for This Report
Table 114. Key Data Information from Secondary Sources
Table 115. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Mitochondrial-based Therapeutics Market Size Year-over-Year 2018-2029 & (US$ Million)
Figure 2. Global Mitochondrial-based Therapeutics Market Size (US$ Million), 2018 VS 2022 VS 2029
Figure 3. Global Mitochondrial-based Therapeutics Market Share by Regions: 2022 VS 2029
Figure 4. Global Mitochondrial-based Therapeutics Forecasted Market Size Share by Region (2024-2029)
Figure 5. North America Mitochondrial-based Therapeutics Market Size Growth Rate (2018-2029) & (US$ Million)
Figure 6. Europe Mitochondrial-based Therapeutics Market Size Growth Rate (2018-2029) & (US$ Million)
Figure 7. Asia-Pacific Mitochondrial-based Therapeutics Market Size Growth Rate (2018-2029) & (US$ Million)
Figure 8. Latin America Mitochondrial-based Therapeutics Market Size Growth Rate (2018-2029) & (US$ Million)
Figure 9. Middle East & Africa Mitochondrial-based Therapeutics Market Size Growth Rate (2018-2029) & (US$ Million)
Figure 10. Product Picture of Oral
Figure 11. Global Oral Market Size (US$ Million) & YoY Growth (2018-2029)
Figure 12. Product Picture of Intravenous
Figure 13. Global Intravenous Market Size (US$ Million) & YoY Growth (2018-2029)
Figure 14. Global Mitochondrial-based Therapeutics Market Size Share by Type: 2022 & 2029
Figure 15. North America Mitochondrial-based Therapeutics Revenue Market Share by Type (2018-2029)
Figure 16. Europe Mitochondrial-based Therapeutics Revenue Market Share by Type (2018-2029)
Figure 17. Asia-Pacific Mitochondrial-based Therapeutics Revenue Market Share by Type (2018-2029)
Figure 18. Latin America Mitochondrial-based Therapeutics Revenue Market Share by Type (2018-2029)
Figure 19. Middle East and Africa Mitochondrial-based Therapeutics Revenue Market Share by Type (2018-2029)
Figure 20. Mitochondrial Myopathy Market Size (US$ Million) & YoY Growth (2018-2029)
Figure 21. Leber’s heredity Optic Neuropathy Market Size (US$ Million) & YoY Growth (2018-2029)
Figure 22. Leigh Syndrome Market Size (US$ Million) & YoY Growth (2018-2029)
Figure 23. Mitochondrial DNA Depletion Syndrome Market Size (US$ Million) & YoY Growth (2018-2029)
Figure 24. Other Market Size (US$ Million) & YoY Growth (2018-2029)
Figure 25. Global Mitochondrial-based Therapeutics Market Size Share by Application: 2022 & 2029
Figure 26. North America Mitochondrial-based Therapeutics Revenue Market Share by Application (2018-2029)
Figure 27. Europe Mitochondrial-based Therapeutics Revenue Market Share by Application (2018-2029)
Figure 28. Asia-Pacific Mitochondrial-based Therapeutics Revenue Market Share by Application (2018-2029)
Figure 29. Latin America Mitochondrial-based Therapeutics Revenue Market Share by Application (2018-2029)
Figure 30. Middle East and Africa Mitochondrial-based Therapeutics Revenue Market Share by Application (2018-2029)
Figure 31. Mitochondrial-based Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
Figure 32. Global Top 5 and Top 10 Players Mitochondrial-based Therapeutics Market Share in 2022
Figure 33. North America Mitochondrial-based Therapeutics Market Share by Country (2018-2029)
Figure 34. United States Mitochondrial-based Therapeutics Market Size (2018-2029) & (US$ Million)
Figure 35. Canada Mitochondrial-based Therapeutics Market Size (2018-2029) & (US$ Million)
Figure 36. Germany Mitochondrial-based Therapeutics Market Size (2018-2029) & (US$ Million)
Figure 37. France Mitochondrial-based Therapeutics Market Size (2018-2029) & (US$ Million)
Figure 38. U.K. Mitochondrial-based Therapeutics Market Size (2018-2029) & (US$ Million)
Figure 39. Italy Mitochondrial-based Therapeutics Market Size (2018-2029) & (US$ Million)
Figure 40. Russia Mitochondrial-based Therapeutics Market Size (2018-2029) & (US$ Million)
Figure 41. Nordic Countries Mitochondrial-based Therapeutics Market Size (2018-2029) & (US$ Million)
Figure 42. Asia-Pacific Mitochondrial-based Therapeutics Market Share by Region (2018-2029)
Figure 43. China Mitochondrial-based Therapeutics Market Size (2018-2029) & (US$ Million)
Figure 44. Japan Mitochondrial-based Therapeutics Market Size (2018-2029) & (US$ Million)
Figure 45. South Korea Mitochondrial-based Therapeutics Market Size (2018-2029) & (US$ Million)
Figure 46. Southeast Asia Mitochondrial-based Therapeutics Market Size (2018-2029) & (US$ Million)
Figure 47. India Mitochondrial-based Therapeutics Market Size (2018-2029) & (US$ Million)
Figure 48. Australia Mitochondrial-based Therapeutics Market Size (2018-2029) & (US$ Million)
Figure 49. Latin America Mitochondrial-based Therapeutics Market Share by Country (2018-2029)
Figure 50. Mexico Mitochondrial-based Therapeutics Market Size (2018-2029) & (US$ Million)
Figure 51. Brazil Mitochondrial-based Therapeutics Market Size (2018-2029) & (US$ Million)
Figure 52. Middle East & Africa Mitochondrial-based Therapeutics Market Share by Country (2018-2029)
Figure 53. Turkey Mitochondrial-based Therapeutics Market Size (2018-2029) & (US$ Million)
Figure 54. Saudi Arabia Mitochondrial-based Therapeutics Market Size (2018-2029) & (US$ Million)
Figure 55. UAE Mitochondrial-based Therapeutics Market Size (2018-2029) & (US$ Million)
Figure 56. Bottom-up and Top-down Approaches for This ReportDescription
Mitochondria are therefore vital for normal cellular function, including intracellular metabolic activities and signal transduction of various cellular pathways. They are involved in cellular ion homeostasis, oxidative stress, and apoptotic and necrotic cell death. Mitochondrial-based Therapeutics report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Mitochondrial-based Therapeutics market is projected to reach US$ 651.3 million in 2029, increasing from US$ 379 million in 2022, with the CAGR of 7.8% during the period of 2023 to 2029. Demand from Mitochondrial Myopathy and Leber’s heredity Optic Neuropathy are the major drivers for the industry.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Mitochondrial-based Therapeutics market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report:
By Company
Reneo Pharmaceutical
Pfizer Inc.
Norvartis AG
Takeda Pharmaceuticals
Amgen Inc.
NeuroVive Pharmaceutical AB
Entogene AG
Stealth Biotherapeutics
Ixchel Pharma
Reata Pharmaceuticals
Segment by Type
Oral
Intravenous
Segment by Application
Mitochondrial Myopathy
Leber’s heredity Optic Neuropathy
Leigh Syndrome
Mitochondrial DNA Depletion Syndrome
Other
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Mitochondrial-based Therapeutics market further:
Chapter 1: Global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029).
Chapter 2: Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 3: Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 4: Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Companies’ Outline, covering company’s basic information, Mitochondrial-based Therapeutics introduction, etc. Mitochondrial-based Therapeutics Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10: Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11: Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12: QYResearch’s Conclusions of Mitochondrial-based Therapeutics market based on comprehensive survey.
Chapter 13: Methodology and Data Sources adopted by QYResearch.
CHOOSE LICENSE TYPE
USD 3350.00
USD 5025.00
USD 6700.00
Add to Cart
Buy Now
Have a question?
English
Simon Lee
English
Hitesh
Chinese
Damon
Japanese
Tang Xin
Korean
Sung-Bin Yoon
General Email:
WHAT QYRESEARCH OFFER?
Competition
Key players, new entrants,acquisitions, mergers and expansions,development trends and challenges.
Industry Analysis
Rawmaterial, application, product type, demand,supply,downstream, supply chain etc.
Market Size
Capacity, production, sales, revenue, price, cost etc.
Customized Information
We can offer customized survey and information to meet ourclient's need.
INTEREST IN THIS REPORT?
Get A Free Sample >>
WHY QYR?
Fastest report delivery service
More than 18 years of vast experience
Operation for 24 * 7 & 365 days
In-depth and comprehensive analysis
Professional and timely after-sales service
Owns large database
Have a question?
English
Simon Lee
English
Hitesh
Chinese
Damon
Japanese
Tang Xin
Korean
Sung-Bin Yoon
General Email:
WHAT QYRESEARCH OFFER?
Competition
Key players, new entrants,acquisitions, mergers and expansions,development trends and challenges.
Industry Analysis
Rawmaterial, application, product type, demand,supply,downstream, supply chain etc.
Market Size
Capacity, production, sales, revenue, price, cost etc.
Customized Information
We can offer customized survey and information to meet ourclient's need.
INTEREST IN THIS REPORT?
Get A Free Sample >>
WHY QYR?
-
Fastest report delivery service
-
More than 18 years of vast experience
-
Operation for 24 * 7 & 365 days
-
In-depth and comprehensive analysis
-
Professional and timely after-sales service
-
Owns large database
Add to Cart
Buy Now